$BKSY
BlackSky Technology Inc.

2020 Q2 Form 10-Q Financial Statement

#000119312520142824 Filed on May 14, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2020 Q1 2019 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $198.4K
YoY Change
Operating Profit -$198.4K -$258.3K -$801.00
YoY Change 19368.3% 32150.44%
Interest Expense $53.52K
YoY Change
% of Operating Profit
Other Income/Expense, Net $53.52K $6.980M
YoY Change
Pretax Income -$144.9K $6.721M -$801.00
YoY Change 14116.39% -839212.36%
Income Tax -$30.42K $278.8K
% Of Pretax Income 4.15%
Net Earnings -$114.4K $6.442M -$801.00
YoY Change 11130.91% -804401.37%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$230.9K
COMMON SHARES
Basic Shares Outstanding 39.53M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $702.6K
YoY Change
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $253.9K
YoY Change
Inventory
Prepaid Expenses $253.9K $233.5K
Receivables
Other Receivables
Total Short-Term Assets $956.5K $1.090M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $318.3M
YoY Change
Other Assets $880.00
YoY Change
Total Long-Term Assets $318.3M $318.4M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $956.5K $1.090M
Total Long-Term Assets $318.3M $318.4M
Total Assets $319.3M $319.5M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $25.00K
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $367.6K $421.7K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $11.07M
YoY Change
Total Long-Term Liabilities $11.07M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $367.6K $421.7K
Total Long-Term Liabilities $11.07M
Total Liabilities $11.44M $11.57M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings $1.283M $1.398M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.000M $5.000M $22.02K
YoY Change
Total Liabilities & Shareholders Equity $319.3M $319.5M
YoY Change

Cashflow Statement

Concept 2020 Q2 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$114.4K $6.442M -$801.00
YoY Change 11130.91% -804401.37%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$664.9K -$342.0K -$801.00
YoY Change 42599.5%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $283.9K
YoY Change
Cash From Investing Activities $283.9K $115.4K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -10.30K
YoY Change
NET CHANGE
Cash From Operating Activities -664.9K -342.0K -801.0
Cash From Investing Activities 283.9K 115.4K
Cash From Financing Activities 0.000 -10.30K
Net Change In Cash -381.0K -226.6K -11.10K
YoY Change 1941.54%
FREE CASH FLOW
Cash From Operating Activities -$664.9K -$342.0K -$801.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Cash
Cash
1083611
CY2020Q1 us-gaap Cash
Cash
856980
CY2020Q1 us-gaap Assets
Assets
319519675
CY2019Q4 us-gaap Assets
Assets
318245958
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
421699
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
276368
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3601398
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4650349
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
5000009
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
319519675
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
318245958
CY2020Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
258326
CY2019Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
801
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9388548
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8250000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
1048954
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-801
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
22823
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
22022
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
5000004
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-342023
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-801
CY2019Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
10300
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-10300
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-226631
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-11101
CY2019Q1 us-gaap Cash
Cash
30960
CY2019Q1 sftwu Deferred Offering Costs Included In Accrued Offering Costs
DeferredOfferingCostsIncludedInAccruedOfferingCosts
12962
CY2018Q4 us-gaap Cash
Cash
42061
CY2020Q1 sftwu Minimum Percentage Of Fair Market Value Of Business Acquisition To Trust Account Balance
MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance
0.80
CY2020Q1 sftwu Business Acquisition Percentage Of Minimum Ownership To Be Acquired
BusinessAcquisitionPercentageOfMinimumOwnershipToBeAcquired
0.50
CY2020Q1 sftwu Public Shares Redemption Percentage Threshold
PublicSharesRedemptionPercentageThreshold
0.15
CY2020Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2020Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
233457
CY2020Q1 us-gaap Assets Current
AssetsCurrent
1090437
CY2019Q4 us-gaap Assets Current
AssetsCurrent
1286083
CY2020Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
318429238
CY2020Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
129020
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
181732
CY2020Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
292679
CY2020Q1 sftwu Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
11068750
CY2019Q4 sftwu Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
11068750
CY2020Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
302949785
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1397670
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
348716
CY2020Q1 us-gaap Liabilities
Liabilities
11569881
CY2019Q4 us-gaap Liabilities
Liabilities
11345118
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
202472
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1361
CY2019Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
316958514
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
94636
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
301900836
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1207866
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
278836
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1586116
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1327790
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-801
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-258326
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-801
CY2020Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
378250
CY2020Q1 sftwu Interest Earned On Marketable Securities Held In Trust Account
InterestEarnedOnMarketableSecuritiesHeldInTrustAccount
1207866
CY2020Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
378250
CY2020Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
80793
CY2020Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
30985
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-52712
CY2020Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
198043
CY2020Q1 sftwu Change In Value Of Common Stock Subject To Possible Redemption
ChangeInValueOfCommonStockSubjectToPossibleRedemption
-1048949
CY2020Q1 us-gaap Temporary Equity Net Income
TemporaryEquityNetIncome
1197433
CY2020Q1 sftwu Net Loss Adjusted
NetLossAdjusted
-148479
CY2019Q1 sftwu Net Loss Adjusted
NetLossAdjusted
-801
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
Osprey Technology Acquisition Corp.
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001753539
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2020Q1 dei Trading Symbol
TradingSymbol
SFTWU
CY2020Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020Q1 dei Entity Shell Company
EntityShellCompany
true
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39531250
CY2020Q1 dei Security12b Title
Security12bTitle
Units, each consisting of oneshare of Class A common stock, $0.0001 par value per share, and one-half of one redeemable warrant.
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 sftwu Description Of Minimum Votes To Be Polled
DescriptionOfMinimumVotesToBePolled
These provisions of the Company’s Amended and Restated Certificate of Incorporation may only be amended if approved by holders of a majority of at least 90% of the Company’s common stock voting in a stockholder meeting.
CY2020Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
30120192
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
30142702
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1237500
CY2020Q1 us-gaap Temporary Equity Net Income
TemporaryEquityNetIncome
1197433
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of estimates </div></div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the condensed financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2020Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentration of credit risk </div></div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7906250
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7906250
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
115392
CY2020Q1 us-gaap Decommissioning Trust Assets Description
DecommissioningTrustAssetsDescription
The Sponsor and the Company&#8217;s officers and directors have agreed (a) to waive their redemption rights with respect to their Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b) not to propose an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation (a) that would modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with a Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination or (b) with respect to any other provision relating to stockholders&#8217; rights or pre-initial Business Combination activity, unless the Company provides the public stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.
CY2020Q1 sftwu Public Shares Redemption Percentage
PublicSharesRedemptionPercentage
1.00
CY2020Q1 us-gaap Revenues
Revenues
0
CY2020Q1 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
79432
CY2020Q1 sftwu Proceeds From Interest Withdrawn For Tax Payments
ProceedsFromInterestWithdrawnForTaxPayments
115392
CY2020Q1 sftwu Change In Value Of Common Stock Subject To Possible Redemption
ChangeInValueOfCommonStockSubjectToPossibleRedemption
-1048949

Files In Submission

Name View Source Status
0001193125-20-142824-index-headers.html Edgar Link pending
0001193125-20-142824-index.html Edgar Link pending
0001193125-20-142824.txt Edgar Link pending
0001193125-20-142824-xbrl.zip Edgar Link pending
d926410d10q.htm Edgar Link pending
d926410dex311.htm Edgar Link pending
d926410dex312.htm Edgar Link pending
d926410dex321.htm Edgar Link pending
d926410dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sftwu-20200331.xml Edgar Link completed
sftwu-20200331.xsd Edgar Link pending
sftwu-20200331_cal.xml Edgar Link unprocessable
sftwu-20200331_def.xml Edgar Link unprocessable
sftwu-20200331_lab.xml Edgar Link unprocessable
sftwu-20200331_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending